Biotechnology News and Research

RSS

Genetic test for autism: Transgenomic licenses exclusive intellectual property from IntegraGen

Transgenomic, Inc. announced today that it has licensed on an exclusive U.S. basis intellectual property from IntegraGen SA that will enable Transgenomic to develop and commercialize a genetic test designed to assess the risk of autism in children who have older siblings diagnosed with an autism spectrum disorder. Under the agreement Transgenomic will develop the test in the Company's CAP-accredited and CLIA-certified laboratory, and anticipates launching the new test in the second quarter of 2010. Financial terms of the agreement were not disclosed.

24 Feb 2010

BioStorage Technologies' Frankfurt facility receives green certification from ENTEGA Vertrieb

BioStorage Technologies, a worldwide provider of long- and short-term storage of biomaterials, sample management and cold chain logistics, today announced its full-service biorepository near Frankfurt, Germany received green certification from ENTEGA Vertrieb GmbH & Co., a leading Germany-based sustainable energy supplier.

24 Feb 2010

Nominations accepted for 2010 George Washington Carver Award

The third annual George Washington Carver Award will recognize significant contributions by an individual to the field of industrial biotechnology, including applications in biological engineering, environmental science, biorefining and biobased products. The Biotechnology Industry Organization today announced that it is accepting nominations for the 2010 George Washington Carver Award, which will be presented at the 2010 World Congress on Industrial Biotechnology and Bioprocessing, June 27-30, 2009 in Washington, D.C.

24 Feb 2010

Sentry BioPharma Services to warehouse and distribute influenza vaccines for CDC

Sentry BioPharma Services announced today that The Centers for Disease Control & Prevention (CDC) selected Sentry to store and distribute influenza vaccine in support of its national strategic reserve. Sentry will warehouse and distribute vaccine from its cGMP, FDA-registered facility located in Indianapolis, Ind. Sentry's vast experience storing and transporting regulated, temperature-sensitive pharmaceutical products will ensure product integrity, supply chain security and fast, efficient distribution of the disease-preventing vaccines.

24 Feb 2010

PAREXEL International expands capabilities by opening new early phase unit in Port Elizabeth, South Africa

PAREXEL International Corporation, a leading global biopharmaceutical services provider, today announced that it has expanded its capabilities through the opening of a new early phase unit in Port Elizabeth, South Africa.

From Parexel 24 Feb 2010

Medical innovation: A real boon for American patients

An article in the Journal Miner recently highlighted the fact that many people are living longer, healthier and more productive lives thanks to medical innovation and research.

24 Feb 2010

New genetic data may help predict risk for end-stage kidney disease

Israeli and American researchers have identified new genetic data that could be used in the future to predict who will develop end-stage kidney disease (ESKD). ESKD requires dialysis or transplantation to sustain life, and is fatal in most regions of the world, where these treatments are not available.

24 Feb 2010

Alliance Biosciences to provide engineering and biosafety guidance for Nyumbani's HIV/TB diagnostic facility

Alliance Biosciences reached an agreement with the Nyumbani Children's Home in Kenya to provide engineering and biosafety guidance to Nyumbani's planned HIV/TB diagnostic facility.

24 Feb 2010

Winner of 2010 Anatrace Membrane Protein Award

Affymetrix, Inc. today announced that Professor Tom Rapoport of Harvard Medical School and Howard Hughes Medical Institute is the winner of the 2010 Anatrace Membrane Protein Award.

24 Feb 2010

CellCentric out-licenses development, commercialisation of novel epigenetic discovery programme to Takeda Pharmaceutical

From its broad portfolio of novel targets in epigenetics, CellCentric has out-licensed exclusively the development and commercialisation of an important programme focused on cancer.

24 Feb 2010

WuXi PharmaTech's Shanghai c-GMP manufacturing facility receives MPA compliance certificate

WuXi PharmaTech (WX), a leading pharmaceutical, biotechnology and medical device research and development outsourcing company with operations in China and the United States, announced today that it received the formal certificate of GMP compliance from the Medical Products Agency (MPA) of Sweden, acting on behalf of the European Medicines Agency (EMEA), for its c-GMP drug product manufacturing and analytical testing facilities located in Shanghai.

24 Feb 2010

New genetic analysis system for forensic DNA testing laboratories launched

Life Technologies Corporation today announced the launch of a new genetic analysis system designed to optimize data quality and deliver increased reliability, performance, quality assurance and ease-of-use specifically for forensic DNA testing laboratories.

24 Feb 2010

Cephalon to acquire Ception Therapeutics following positive clinical study of eosinophilic asthma

Cephalon, Inc. (Nasdaq: CEPH) announced today that it has exercised its option to acquire Ception Therapeutics, Inc., following receipt of positive data from a clinical study in adults with eosinophilic asthma.

23 Feb 2010

Cantimer, Advanced Instruments announce license and product development agreement

Cantimer, Inc., and Advanced Instruments, Inc. today jointly announced that the two companies had signed a license and product development agreement. Under the terms of the license agreement, Advanced Instruments received an exclusive license to Cantimer's unique sensor technology for select applications in the biotech market.

23 Feb 2010

Gross sales of Acorda Therapeutics' ZANAFLEX CAPSULES and tablets increase 9.1% to $58.3M in 2009

Acorda Therapeutics, Inc. today announced its financial results for the fourth quarter and full year ended December 31, 2009.

23 Feb 2010

Genentech's Avastin combination Phase III study in advanced stomach cancer does not meet primary endpoint

Genentech, Inc., a wholly owned member of the Roche Group, today announced that a Phase III study (AVAGAST) did not meet its primary endpoint of showing Avastin® (bevacizumab) plus Xeloda® (capecitabine) or 5-FU and cisplatin chemotherapy extended the lives of people with inoperable or advanced stomach (gastric) cancer, compared to chemotherapy alone.

23 Feb 2010

LinkMed reports increased sales revenues for 2009 fourth quarter

“Operating income in 2009 was SEK 18.7 million despite non-recurring costs of SEK 3.9 million in the second half of the year related to the transition to an in-house sales organi-zation in the transplantation sector".

23 Feb 2010

Enzymerx completes enrollment for clinical trial of pegsitacase

EnzymeRx, LLC, a clinical-stage biotechnology company, announced completion of the enrollment of its first clinical trial of pegsitacase (formerly called Uricase-PEG 20), and the recent launch of a second clinical study. Pegsitacase is a pegylated uricase being developed by EnzymeRx for the treatment of refractory gout and for the management of hyperuricemia associated with tumor lysis syndrome.

22 Feb 2010

OrbiMed announces next venture capital fund for investments in biopharmaceutical and medical device companies

OrbiMed, a leading investment management firm focused on the healthcare sector, is pleased to announce the launch of its next venture capital fund, Caduceus Private Investments IV, LP, with $550 million in limited partner commitments. Approximately 80% of the new fund’s capital is from returning investors, and the fund’s partners include some of the largest pension plans, endowments, foundations, and sovereign funds globally.

22 Feb 2010

WuXi PharmaTech's Suzhou non-clinical safety testing facility receives AAALAC accreditation

WuXi PharmaTech, a leading pharmaceutical, biotechnology and medical device research and development outsourcing company with operations in China and the United States, announced today that its Suzhou non-clinical safety testing facility received full accreditation from the Association for the Assessment and Accreditation of Laboratory Animal Care International (AAALAC). As a result of an extensive on-site evaluation, AAALAC determined that WuXi PharmaTech's facility meets the highest standards of animal care and research practices.

22 Feb 2010

Biotechnology News and Research

Genetic test for autism: Transgenomic licenses exclusive intellectual property from IntegraGen

BioStorage Technologies' Frankfurt facility receives green certification from ENTEGA Vertrieb

Nominations accepted for 2010 George Washington Carver Award

Sentry BioPharma Services to warehouse and distribute influenza vaccines for CDC

PAREXEL International expands capabilities by opening new early phase unit in Port Elizabeth, South Africa

Medical innovation: A real boon for American patients

New genetic data may help predict risk for end-stage kidney disease

Alliance Biosciences to provide engineering and biosafety guidance for Nyumbani's HIV/TB diagnostic facility

Winner of 2010 Anatrace Membrane Protein Award

CellCentric out-licenses development, commercialisation of novel epigenetic discovery programme to Takeda Pharmaceutical

WuXi PharmaTech's Shanghai c-GMP manufacturing facility receives MPA compliance certificate

New genetic analysis system for forensic DNA testing laboratories launched

Cephalon to acquire Ception Therapeutics following positive clinical study of eosinophilic asthma

Cantimer, Advanced Instruments announce license and product development agreement

Gross sales of Acorda Therapeutics' ZANAFLEX CAPSULES and tablets increase 9.1% to $58.3M in 2009

Genentech's Avastin combination Phase III study in advanced stomach cancer does not meet primary endpoint

LinkMed reports increased sales revenues for 2009 fourth quarter

Enzymerx completes enrollment for clinical trial of pegsitacase

OrbiMed announces next venture capital fund for investments in biopharmaceutical and medical device companies

WuXi PharmaTech's Suzhou non-clinical safety testing facility receives AAALAC accreditation

Event guide: 3rd IMPACCT Real World Evidence Summit Europe eBook

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News